topic

752 The impact of grade of differentiation and BRAF mutation status on neoantigen and immune landscape in papillary thyroid cancer
Myungwoo Nam, Myungwoo Nam, Woojung Yang, Ju Young Lee, Jaeyoun Choi, Hansol Choi, Emma Yu, Eugene Kim, Jin Young Hwang, William Bae, Chan Mi Jung, Victor Wang, Jeffrey Chuang, Young Kwang Chae

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A451; DOI: 10.1136/jitc-2020-SITC2020.0752
760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brian Piening, Brendan Curti, Walter Urba, William Redmond

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A455-A456; DOI: 10.1136/jitc-2020-SITC2020.0760
762 A combination of functional biomarkers improves identification of the tumor-specific reactive T cell repertoire
Arianna Draghi, Katja Harbst, Inge Svane, Marco Donia

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A457; DOI: 10.1136/jitc-2020-SITC2020.0762
768 Re-directed T cell therapy to control invasive aspergillosis
Karishma Bavisi, Sebastian Wurster, Nathaniel Albert, Sattva Neelapu, Dimitrios P Kontoyiannis, Pappanaicken Kumaresan

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A459-A460; DOI: 10.1136/jitc-2020-SITC2020.0768
766 Novel bioluminescent bioassays for the discovery and development of T cell redirecting cancer therapies
Vanessa Ott, Julia Gilden, Jamison Grailer, Michael Slater, Pete Stecha, Jim Hartnett, Dan Lazar, Frank Fan, Mei Cong, Zhijie Jey Cheng

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A459; DOI: 10.1136/jitc-2020-SITC2020.0766
75 Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer
Dante Bortone, Steven Vensko, Sarah Entwistle, Alexandria Cogdill, Anne Monette, Yana Najjar, Randy Sweis, Nicholas Tschernia, Erik Wennerberg, Praveen Bommareddy, Cara Haymaker, Uqba Khan, Heather McGee, Wungki Park, Houssein Sater, Christine Spencer, Maria Ascierto, Valentin Barsan, Vinita Popat, Sara Valpione, Danny Wells, Vésteinn Thorsson, Roberta Zappasodi, Nils Rudqvist, Benjamin Vincent

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A46-A47; DOI: 10.1136/jitc-2020-SITC2020.0075
769 CAR T cells undergoing epigenetic reprogramming by low-dose decitabine enhances persistent anti-tumor efficacy in vivo
Yao Wang, Weidong Han, Chuan Tong, Zhiqianag Wu, Hanren Dai

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A460-A461; DOI: 10.1136/jitc-2020-SITC2020.0769
782 ALDH1A inhibition as adjuvant to ovarian cancer immunotherapy
Bingsi Gao, Mainpal Rana, Dongli Yang, Edward Grimley, Stacy McGonigal, Ronald Buckanovich, Anda Vlad

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A469; DOI: 10.1136/jitc-2020-SITC2020.0782
785 Estrogen-deprivation promotes Th1 polarization of tumor-associated T cells in a mouse model of high grade serous ovarian cancer
Daniel Falcon, Marina Miller, Chelsea Goff, Ichiko Kinjyo, Sarah Adams

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A469-A470; DOI: 10.1136/jitc-2020-SITC2020.0785
77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
Ming-Mo Hou, Kun-Ming Rau, Yoon-Koo Kang, Jong-Seok Lee, Hongming Pan, Ying Yuan, Cunjing Yu, Yun Zhang, Xiaopeng Ma, Xikun Wu, Xin Li, Katie Wood, Chia-Jui Yen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A47-A48; DOI: 10.1136/jitc-2020-SITC2020.0077

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages